Instead of an exclusive deal, Zymeworks shared its platform non-exclusively with multiple pharma giants. This multi-partner strategy validated the technology, generated capital, and built a portfolio of royalty interests before the company developed its own internal pipeline.

Synthakyne operates as a specialized 'cytokine engineering shop.' It develops its own assets in high-value areas like oncology (IL-2, IL-12) while simultaneously licensing its platform for other indications, such as inflammation, through major partnerships with Merck and Sanofi. This strategy generates capital and validates the core technology.

Biotech business models have shifted from a high-risk, asset-centric approach to a platform-based model. Companies now focus on securing multiple early-stage partnerships, which is more capital-efficient and preserves optionality in a rapidly changing therapeutic landscape.

The company's drug discovery platform was built out of necessity to identify combination therapies for aging. Having proven its value internally, the strategic plan for the next 12-24 months includes making it commercially available through collaborations. This creates a new potential revenue stream and leverages an internal asset for external partnerships, diversifying the business model beyond its own pipeline.

Beyond developing its own drug portfolio, Monterosa strategically leverages its discovery platform for partnerships with companies like Roche and Novartis. These deals have provided over $300 million in non-dilutive capital, funding operations without giving away equity.

For pre-revenue biotechs like Voyager, partnering provides non-dilutive capital. More importantly, it de-risks development by sharing costs and leveraging a larger company's resources and expertise. This can increase a drug's probability of success, a crucial factor when most programs fail.

Previously, it was believed the only path to value in biotech was developing a drug. Now, AI models are proving so effective at accelerating R&D that traditional software and platform business models are becoming highly valuable and viable for serving large pharma customers.

Eupraxia views its delivery technology as a broad platform beyond one drug. It employs a dual strategy: advancing its own pipeline of proprietary drugs in-house while simultaneously seeking external partnerships for other applications, like cancer therapy. This hybrid model diversifies opportunities and aims to maximize the technology's value across multiple therapeutic areas.

To manage the long, costly timeline of therapeutic development, a biotech can create revenue-generating subsidiaries. One can offer its platform as a service (like a CDMO), while another sells lower-regulation products like cosmetic ingredients for faster market entry. This provides crucial cash flow to sustain the core drug pipeline.